S&P 500   4,600.95 (+1.38%)
DOW   35,283.63 (+2.03%)
QQQ   385.17 (+0.53%)
AAPL   166.07 (+2.61%)
MSFT   323.38 (+0.11%)
FB   316.27 (+3.07%)
GOOGL   2,857.67 (+0.62%)
AMZN   3,457.88 (+2.01%)
TSLA   998.64 (-1.61%)
NVDA   293.00 (-4.54%)
BABA   121.70 (+8.70%)
NIO   31.98 (-0.53%)
CGC   10.07 (+0.80%)
AMD   136.22 (-5.41%)
GE   96.63 (+4.16%)
MU   82.33 (+0.87%)
T   23.45 (-0.04%)
F   19.27 (+0.68%)
DIS   150.28 (+2.78%)
PFE   52.16 (-3.89%)
AMC   28.66 (-1.21%)
ACB   5.92 (+1.72%)
BA   205.32 (+3.44%)
S&P 500   4,600.95 (+1.38%)
DOW   35,283.63 (+2.03%)
QQQ   385.17 (+0.53%)
AAPL   166.07 (+2.61%)
MSFT   323.38 (+0.11%)
FB   316.27 (+3.07%)
GOOGL   2,857.67 (+0.62%)
AMZN   3,457.88 (+2.01%)
TSLA   998.64 (-1.61%)
NVDA   293.00 (-4.54%)
BABA   121.70 (+8.70%)
NIO   31.98 (-0.53%)
CGC   10.07 (+0.80%)
AMD   136.22 (-5.41%)
GE   96.63 (+4.16%)
MU   82.33 (+0.87%)
T   23.45 (-0.04%)
F   19.27 (+0.68%)
DIS   150.28 (+2.78%)
PFE   52.16 (-3.89%)
AMC   28.66 (-1.21%)
ACB   5.92 (+1.72%)
BA   205.32 (+3.44%)
S&P 500   4,600.95 (+1.38%)
DOW   35,283.63 (+2.03%)
QQQ   385.17 (+0.53%)
AAPL   166.07 (+2.61%)
MSFT   323.38 (+0.11%)
FB   316.27 (+3.07%)
GOOGL   2,857.67 (+0.62%)
AMZN   3,457.88 (+2.01%)
TSLA   998.64 (-1.61%)
NVDA   293.00 (-4.54%)
BABA   121.70 (+8.70%)
NIO   31.98 (-0.53%)
CGC   10.07 (+0.80%)
AMD   136.22 (-5.41%)
GE   96.63 (+4.16%)
MU   82.33 (+0.87%)
T   23.45 (-0.04%)
F   19.27 (+0.68%)
DIS   150.28 (+2.78%)
PFE   52.16 (-3.89%)
AMC   28.66 (-1.21%)
ACB   5.92 (+1.72%)
BA   205.32 (+3.44%)
S&P 500   4,600.95 (+1.38%)
DOW   35,283.63 (+2.03%)
QQQ   385.17 (+0.53%)
AAPL   166.07 (+2.61%)
MSFT   323.38 (+0.11%)
FB   316.27 (+3.07%)
GOOGL   2,857.67 (+0.62%)
AMZN   3,457.88 (+2.01%)
TSLA   998.64 (-1.61%)
NVDA   293.00 (-4.54%)
BABA   121.70 (+8.70%)
NIO   31.98 (-0.53%)
CGC   10.07 (+0.80%)
AMD   136.22 (-5.41%)
GE   96.63 (+4.16%)
MU   82.33 (+0.87%)
T   23.45 (-0.04%)
F   19.27 (+0.68%)
DIS   150.28 (+2.78%)
PFE   52.16 (-3.89%)
AMC   28.66 (-1.21%)
ACB   5.92 (+1.72%)
BA   205.32 (+3.44%)
NASDAQ:KTTA

Pasithea Therapeutics News Headlines

$2.85
+0.05 (+1.79%)
(As of 12/6/2021 12:52 PM ET)
Add
Compare
Today's Range
$2.55
$2.97
50-Day Range
$2.21
$5.60
52-Week Range
$2.10
$8.50
Volume
29,972 shs
Average Volume
4.90 million shs
Market Capitalization
$37.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Media Mentions By Week



Pasithea Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

KTTA
News Sentiment

0.67

0.35

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

KTTA Articles
This Week

3

2

KTTA Articles
Average Week

Get Pasithea Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter.

Pasithea Therapeutics (NASDAQ:KTTA) News Headlines Today

SourceHeadline
finance.yahoo.com logoPasithea Therapeutics Expands its Mobile Clinics into Florida and Nevada
finance.yahoo.com - December 1 at 12:58 PM
benzinga.com logoEXCLUSIVE: Pasithea Therapeutics Expands Its Ketamine Therapy Mobile Clinics Into Florida, Nevada
benzinga.com - December 1 at 7:58 AM
finance.yahoo.com logoPasithea Therapeutics Corp. Announces Closing of $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules
finance.yahoo.com - November 29 at 8:12 PM
nasdaq.com logoPasithea Therapeutics Corp Shares Close the Week 66.3% Higher - Weekly Wrap
nasdaq.com - November 27 at 12:01 AM
finance.yahoo.com logoPasithea Therapeutics Corp. Announces Pricing of a $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules
finance.yahoo.com - November 24 at 10:12 AM
finance.yahoo.com logo5 Top Stock Gainers for Tuesday Climb After Powell Renomination
finance.yahoo.com - November 23 at 6:40 PM
markets.businessinsider.com logoMid-Day Market Update: Nasdaq Tumbles Over 200 Points; Pasithea Therapeutics Shares Surge
markets.businessinsider.com - November 23 at 1:40 PM
msn.com logoEXCLUSIVE: Pasithea's Depression Treatment, Esketamine Nasal Spray Added In Clinic Offerings In UK
msn.com - November 23 at 8:39 AM
finance.yahoo.com logoPasithea Therapeutics Adds Esketamine Nasal Spray to its Clinic Offerings in the U.K.
finance.yahoo.com - November 23 at 8:39 AM
finance.yahoo.com logoPasithea Therapeutics Launches In-Home Intravenous Ketamine Therapy in Major U.S. Cities, Expanding its International Footprint
finance.yahoo.com - November 17 at 8:34 AM
benzinga.com logoEXCLUSIVE: Pasithea Clinics Launches In-Home Intravenous Ketamine Therapy In Major US Cities
benzinga.com - November 17 at 7:37 AM
finance.yahoo.com logoBiotech Company Pasithea Therapeutics Founders on Entrepreneurship in Science
finance.yahoo.com - November 15 at 1:54 PM
au.finance.yahoo.com logoPasithea Therapeutics Collaborates with Renowned Musician and Producer to Create Soundtracks for Ketamine Therapy
au.finance.yahoo.com - November 11 at 12:25 PM
finance.yahoo.com logoPasithea Therapeutics Corp. Establishes Scientific Advisory Board and Names Dr. Charles B. Nemeroff as Chair
finance.yahoo.com - November 9 at 12:58 PM
reuters.com logoPasithea Therapeutics Corp
reuters.com - October 29 at 7:15 PM
investorplace.com logoPasithea Therapeutics Corp (KTTA)
investorplace.com - October 28 at 12:59 PM
finance.yahoo.com logoBiotech Companies Are Embracing the Growing Psychedelic Drug Market To Confront a Global Increase in Depression and Anxiety
finance.yahoo.com - October 28 at 12:59 PM
finance.yahoo.com logoEXCLUSIVE: Pasithea Administers First IV Ketamine Infusion Therapy In Depression Patients
finance.yahoo.com - October 27 at 10:40 AM
finance.yahoo.com logoPasithea Therapeutics Announces Successful Treatment of First Patients in the UK with Ketamine Infusion Therapy
finance.yahoo.com - October 27 at 10:40 AM
finance.yahoo.com logoThis Company Just Extended its Reach into the United Kingdom by Opening its First Ketamine Therapy Clinic
finance.yahoo.com - October 19 at 9:37 AM
Get Pasithea Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 12/6/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.